Analysts expect Flex Pharma Inc (NASDAQ:FLKS) to announce earnings per share of ($0.85) for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Flex Pharma’s earnings. The highest EPS estimate is ($0.53) and the lowest is ($1.42). Flex Pharma posted earnings per share of ($0.41) in the same quarter last year, which would suggest a negative year-over-year growth rate of 107.3%. The business is expected to issue its next quarterly earnings report on Wednesday, March 14th.
On average, analysts expect that Flex Pharma will report full-year earnings of ($2.40) per share for the current year, with EPS estimates ranging from ($3.23) to ($2.08). For the next year, analysts forecast that the business will post earnings of ($2.44) per share, with EPS estimates ranging from ($3.68) to ($1.42). Zacks’ earnings per share averages are a mean average based on a survey of research firms that follow Flex Pharma.
Flex Pharma (NASDAQ:FLKS) last announced its earnings results on Monday, November 6th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.60) by $0.06. The firm had revenue of $0.41 million for the quarter, compared to analysts’ expectations of $0.47 million. Flex Pharma had a negative net margin of 2,655.19% and a negative return on equity of 71.39%.
FLKS has been the topic of several recent research reports. Cantor Fitzgerald restated a “hold” rating and set a $10.00 target price on shares of Flex Pharma in a research report on Monday, September 25th. Zacks Investment Research upgraded shares of Flex Pharma from a “hold” rating to a “buy” rating and set a $3.75 target price on the stock in a research report on Tuesday, October 3rd. Finally, Roth Capital restated a “buy” rating and set a $12.00 target price on shares of Flex Pharma in a research report on Wednesday, January 3rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. Flex Pharma presently has an average rating of “Hold” and a consensus price target of $9.35.
Shares of Flex Pharma (FLKS) traded down $0.10 during midday trading on Thursday, hitting $3.85. 40,573 shares of the stock traded hands, compared to its average volume of 59,724. The stock has a market cap of $69.19, a PE ratio of -1.91 and a beta of 3.54. Flex Pharma has a 52-week low of $2.68 and a 52-week high of $5.93.
A hedge fund recently raised its stake in Flex Pharma stock. Ameriprise Financial Inc. boosted its position in shares of Flex Pharma Inc (NASDAQ:FLKS) by 69.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 654,825 shares of the biotechnology company’s stock after purchasing an additional 268,505 shares during the period. Ameriprise Financial Inc. owned about 3.82% of Flex Pharma worth $2,520,000 as of its most recent SEC filing. 27.31% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “Flex Pharma Inc (FLKS) Expected to Post Earnings of -$0.85 Per Share” was first posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://ledgergazette.com/2018/01/21/flex-pharma-inc-flks-expected-to-post-earnings-of-0-85-per-share.html.
About Flex Pharma
Flex Pharma, Inc is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Flex Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flex Pharma and related companies with MarketBeat.com's FREE daily email newsletter.